Drug intelligence / Profile preview

RO7011785

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO7011785 is a small molecule, selective Toll-like receptor 7 (TLR7) agonist developed by Roche for the treatment of chronic hepatitis B virus (HBV) infection. It is the active metabolite of the oral double prodrug ruzotolimod (also known as RO7020531 or RG7854). RO7011785 acts as an immunomodulator that activates TLR7, thereby stimulating the innate immune system and inducing the production of interferons and interferon-stimulated genes. This immune activation is intended to enhance the host's ability to clear HBV and achieve a functional cure. Clinical development reached Phase II, but Roche discontinued the program for chronic hepatitis B in 2021.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on RO7011785.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7011785.

Explore the full profile